Merck KGaA is making its largest acquisition since buying Sigma-Aldrich for $17 billion in 2014. The German pharmaceutical and life sciences company agreed on Wednesday to acquire Bio-Techne, a Minnesota-based maker of reagents, proteins, and antibodies used in drug development and scientific research, for $73 per share in cash, valuing the deal at $11.3 billion in enterprise value.
Bio-Techne shares surged more than 20% in premarket trading on the news. The offer price represents a 36% premium to Bio-Techne’s one-month volume-weighted average trading price.
What Merck Is Buying
Bio-Techne is not a household name, but it is one of the most important plumbing companies in the life sciences industry. Its products, including biological reagents, recombinant proteins, and analytical instruments, are the building blocks that researchers and drug developers use to discover, test, and manufacture new therapies. Think of it as the picks-and-shovels play for the biotech gold rush.
Bloomberg Law reported that the acquisition will be funded through a combination of existing cash on hand and proceeds from new debt. Merck expects the deal to be immediately accretive to sales and margins, with roughly 140 million euros in annual cost synergies by year three.
The strategic logic is straightforward: Merck’s life sciences division already sells lab supplies and equipment. Adding Bio-Techne’s specialized reagent and protein portfolio fills gaps in its product catalog and gives it deeper penetration into the biologics and cell-and-gene therapy workflows that represent the fastest-growing segments of pharmaceutical R&D.
Why This Deal Happened Now
The timing reflects two forces converging. First, Bio-Techne’s stock had pulled back significantly from its pandemic-era highs, when the broader life sciences tools sector traded at inflated multiples. The 36% premium looks generous against the one-month average but is modest relative to where Bio-Techne traded in 2021.
Second, the biologics market is entering a sustained growth phase driven by GLP-1 drugs, cell therapies, and mRNA-based treatments that require precisely the kinds of specialized reagents and proteins Bio-Techne makes. Merck is not buying at the peak of the cycle. It is buying the toolmaker before the next wave of demand arrives.
The Competitive Landscape
This deal reshapes the competitive dynamics in life sciences tools, a market dominated by a handful of large players including Thermo Fisher Scientific, Danaher, and Agilent Technologies. Merck’s existing life sciences division generated approximately 10 billion euros in revenue last year. Adding Bio-Techne’s roughly $1.2 billion in annual revenue and its high-margin reagent portfolio positions Merck as a stronger competitor in a sector where consolidation is accelerating against Thermo Fisher, which has been the dominant force in the sector since its $21 billion acquisition of Life Technologies in 2014.
The deal is expected to close by the end of 2026 or early 2027, subject to Bio-Techne shareholder approval and regulatory clearance. Merck’s official announcement noted the deal as the latest in a wave of consolidation in life sciences tools, where scale and breadth of product offering increasingly determine which suppliers win long-term contracts with pharma and biotech customers.
What It Means for the Sector
The life sciences tools sector has been waiting for deal activity to pick up after a quiet stretch in 2024 and 2025. This acquisition signals that the big players are ready to deploy capital again, and that the target valuations have come down enough to make acquisitions accretive without heroic assumptions.
For investors, the deal confirms that biological research tools remain a durable, high-margin business with structural tailwinds. For Bio-Techne’s employees in Minneapolis, the question is how much operational independence Merck will preserve, given the company’s track record of integrating Sigma-Aldrich while maintaining its brand and customer relationships.